Novo Nordisk says semaglutide cut obesity rates in young children in trial - Reuters
Novo Nordisk says semaglutide cut obesity rates in young children in trial Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQU1lrLUNXcjU5bHFWSGphdUl6aTlGT0FlYWF4ZUlZNDlabHdUNi1sMVBBRjhPQk41cTA1YlFXbEJEek9uQUVMYmlTTkZPZ3J0NzVDeVZsNmFDRW5YZloyc1Z2dkp5em55ZUVNLXNkcWRhalhMclU1bWYxM1h6a0ZCNTJGdjVtaHZFQnlLSDA4MGVhNjBleGRsdVJpUWxOemtBcmFqQi1ycm5RNU8yNGFKa1ZGamljSktPeDJrYUU0RS1TUU5nVU95aldJMVZxMFhMVVBEd2Uxbw?oc=5" target="_blank">Novo Nordisk says semaglutide cut obesity rates in young children in trial</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight - Reuters
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight Reuters
October 7, 2026 at 07:39 AMNew global guidelines warn against obesity drugs for children under 10
Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization
October 7, 2026 at 08:07 AMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMHalozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PM